Abstract
Orally administered tolamolol, a new cardioselective beta-adrenergic blocking drug, was evaluated in 30 patients with supraventricular arrhythmias or digitalis-induced arrhythmias. Tolamolol therapy slowed the rapid ventricular rate in ten of ten patients with atrial fibrillation and converted two of these ten patients to sinus rhythm. It slowed the rapid ventricular rate in eight of eight patients with atrial flutter and converted two of these eight cases to sinus rhythm. It converted to sinus rhythm four of four patients with paroxysmal atrial tachycardia or paroxysmal atrioventricular AV junctional tachycardia. It abolished supraventricular premature ventricular beats in three of three patients. It abolished digitalis-induced paroxysmal atrial tachycardia with AV block in three of three patients, digitalis-induced premature ventricular contractions in three of three patients, and digitalis-induced AV junctional tachycardia in one patient. Oral administration was effective in treating supraventricular arrhythmias and certain digitalis-induced arrhythmias.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
